MoonLake Submits BLA to FDA for Sonelokimab in Hidradenitis Suppurativa
MLTX sits 94% above its 52-week low of $6.08.
Summary
MoonLake Immunotherapeutics submitted a BLA to the FDA for sonelokimab in moderate-to-severe hidradenitis suppurativa, with FDA acceptance expected within ~60 days and a review timeline within ~74 days.
Key Events · Product Development and Regulatory · MLTX
-
BLA Submitted to FDA
A Biologics License Application has been submitted for sonelokimab, targeting moderate-to-severe hidradenitis suppurativa in adults and pediatric patients 12 years and older.
-
FDA Acceptance Timeline
FDA notification of BLA acceptance is expected within approximately 60 days, with the planned review timeline to follow within approximately 74 days.
-
Expanded Indication Opportunity
This BLA targets hidradenitis suppurativa, a separate indication from the psoriatic arthritis data announced in August, broadening sonelokimab's commercial potential.
-
Cash Runway Supports Launch
With $537 million in cash as of Q2 2026 funding operations into mid-2028, sufficient capital is available to support potential commercialization.
Analysis · MLTX · Life Sciences
A major regulatory milestone has been reached with the submission of MoonLake's first Biologics License Application to the FDA, seeking approval of sonelokimab for moderate-to-severe hidradenitis suppurativa. This moves the company from clinical-stage to potential commercialization. The FDA is expected to confirm acceptance within about 60 days and provide a review timeline within about 74 days. The submission follows positive Phase 3 IZAR-1 data in psoriatic arthritis announced in August, but this BLA targets a different indication — hidradenitis suppurativa — expanding the drug's commercial opportunity. With $537 million in cash funding operations into mid-2028, the company is well-positioned to support a launch if approved.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLTX was trading at $11.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $995.7M. The 52-week trading range was $6.08 to $23.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.